CBD Market

CBD Market Outlook

The global cannabidiol (CBD) market will hit US$ 3 Bn by 2021. The market for cannabidiol products further expand to surpass US$ 34 Bn by 2031, expanding more than 11x, thanks to rising demand for full legalization and a ready consumer base.

Consumption Analysis of CBD from 2016-2020 Vs Future Outlook 2021-2031

The global market for CBD was worth US$ 2.9 Bn in 2020, expanding at an impressive CAGR. The demand for cannabidiol (CBD) for health and wellness purposes is strong due to its therapeutic characteristics, which is a major factor driving market growth.

Furthermore, increased product acceptance and use as a result of regulatory approvals are likely to promote CBD-infused product production.

A growing understanding of CBD's therapeutic potential has inspired a buyer to purchase cannabidiol products regardless of price. Commercial merchants are now focusing on marketing cannabis-based items since they offer a higher profit margin.

According to Fact.MR- a market research and competitive intelligence provider- the market is predicted to increase nearly 28% CAGR from 2021 to 2031.

How is Alleviation of Restrictions Fuelling CBD Products Demand?

Cannabis comprises over 100 chemical compounds known as cannabinoids, with the most common among them being CBD and THC. The World Health Organization’s Expert Committee on Drug Dependence (ECDD) published a report in 2017, which acknowledges clinical employment of CBD to be the most advanced treatment of epilepsy.

CBD is perceived to have significant therapeutic value for seizures on account of epilepsy and relevant conditions. In addition, clinical trials conducted on CBD have depicted its efficacy in treatment of various forms of epilepsy. Based on this development, countries are seeking to incorporate CBD-based therapeutics which will significantly generate demand.

Increasing Application of Marijuana-based CBD Products Fueling Expansion?

By 2028, marijuana based cannabidiol industry is expected to be worth US$ 31 Bn. CBD is derived as an oil or a powder from marijuana plants. These can be blended into lotions or gels, or put into capsules and ingested or applied to the skin.

Tetrahydrocannabinol (THC) is also used in the creation of medications to treat neurological illnesses like dementia, Alzheimer's disease, epilepsy, and other conditions. Because of its psychotropic characteristics, THC is heavily restricted in the majority of countries; as a result, it is expected to grow slowly in comparison to hemp.

Side-effects associated with CBD Products to Impede Adoption?

Cannabidiol is well-known for its ability to cure a variety of illnesses, including anxiety, seizures, neurological problems, cancer-related nausea, chronic pain, and more. Despite being useful for a variety of medical illnesses, studies and research conducted by numerous organizations have shown that CBD-based medicines can nevertheless have minor negative effects.

Dry mouth, drowsiness, low blood pressure, and lightheadedness are just a few of the negative effects experienced by consumers. CBD is also known to raise the level of coumadin (a blood thinner) in the body, which can interact with other drugs and cause negative side effects. These factors might impede future adoption of CBD for therapeutic purposes.

Demand of CBD in Pharmaceutical Applications

In addition, cannabidiol reverses hemorrhoids, avoids menstrual cramps, and lowers psychotic events of schizophrenia.

Top CBD companies are promoting it as a ‘no-side effect’ ingredient in pharmaceutical drugs, which makes it a viable alternative to THC (Tetrahydrocannabinol).

While THC shows its effect in the central nervous system (CNS), cannabidiol does the same in the immune system.

Nevertheless, Cannabidiol and THC, after combining in equal ratios, complement each other’s positive impacts – the “entourage” effect, which can influence emerging trends in the cannabidiol market in the coming years.

Apart from pharmaceuticals, Cannabidiol is steadily finding its way in eateries and breweries as well as an ingredient in mocktails, sodas, and others, owing to its anti-anxiety impact.

However, government bodies across the world are imposing restrictions on the addition of cannabidiol in beverages and food items amid anecdotal clinical evidence, despite the industrial hemp having received a green signal, leaving consumers bewildered about the effects of Cannabidiol.

Furthermore, legal agencies are confiscating consumables offered by restaurant owners, and food manufacturers, which may impact the growth of the cannabidiol market in the coming years.

Improving Accessibility to CBD-based Therapies: WHO Report Aids Alleviation of Restrictions on Cannabidiol

Cannabis comprises over 100 chemical compounds known as cannabinoids, with the most common among them being CBD and THC. The WHO’s Expert Committee on Drug Dependence (ECDD) published a report in 2017, which acknowledges clinical employment of CBD to be the most advanced treatment of epilepsy.

CBD is perceived to have significant therapeutic value for seizures on account of epilepsy and relevant conditions. In addition, clinical trials conducted on CBD have depicted its efficacy in treatment of various forms of epilepsy.

The report further acknowledged existence of primary evidence underpinning utilization of CBD in treatment and management of various other diseases that include Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, rheumatoid arthritis, Crohn’s disease and Huntington’s disease.

ECDD’s conclusion states that current state of research with regard to scheduling of CBD is not justified, and it could impact accessibility for medical and scientific research.

ECDD’s impending final recommendations, to be published soon, will reaffirm or reinforce these conclusions, in order to alleviate legitimate basis for Secretary of Department of Health in maintaining present restrictions on CBD. This will not only relieve burden from companies developing medicinal products, but also improve access for consumers to effective and novel therapies.

CBD Industry Report Scope

Attribute	Details
Forecast Period	2021-2031
Historical Data Available for	2016-2020
Market Analysis	US$ Mn for Value & ‘000 Units for Volume
Key Regions Covered	North America Latin America Europe East Asia South Asia Oceania Middle East & Africa
Key Countries Covered	U.S Canada Brazil Mexico Germany U.K France Spain Italy Russia China Japan South Korea India Australia GCC South Africa
Key Market Segments Covered	Source Form Grade Application Region
Key Companies Profiled	INSYS Therapeutics, Inc. EPIDIOLEX Nightfood Holdings SolMic GmbH Pivot Pharmaceuticals Inc. Marijuana Company of America Inc. HoneyB Healthy Nightfood Holdings
Pricing	Available upon Request

Competitive Landscape

In the following decade, manufacturers in the Cannabidiol industry will focus on strategic acquisitions, collaborations, and new launches.

1. Greenheart CBD, an Irish company, became the first CBD manufacturer to launch a decentralized financial token in March 2021. The token will aid the company's expansion and provide token holders with cost-effective products.
2. With a new CBD nutraceutical to be packaged by ALKM and marketed by USMJ, PAOG hopes to tap into an US$ 18 billion market opportunity. PAOG is on pace to introduce a CBD Nutraceuticals range of products that will generate income this year, in 2021.

Key Segments Covered in CBD Industry Survey

• Source

  • Hemp-based CBD
  • Marijuana-based CBD

• Form

  • CBD Processed Oil
  • CBD Distillate
  • CBD Isolate

• Grade

  • Food Grade CBD
  • Therapeutic Grade CBD

• Application

  • CBD for Food & Beverage
  • CBD for Cosmetics & Personal Care
  • CBD for Pharmaceuticals
  • CBD for Other Applications